MedTrace Logo

Camrelizumab and Chemotherapy Combined With Endoscopic Surgery for Recurrent Nasopharyngeal Carcinoma

NCT05011227 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2024-03-06

No results posted yet for this study

Summary

To explore the effect of Camrelizumab and chemotherapy combining with endoscopic surgery in the treatment of recurrent nasopharyngeal carcinoma.

Conditions

  • Recurrent Nasopharyngeal Carcinoma

Interventions

DRUG

Camrelizumab

2 cycles Camrelizumab before endoscopic surgery and one year after

DRUG

Chemotherapy

2 cycles Gemcitabine based chemotherapy before endoscopic surgery, with or without after surgery

PROCEDURE

endoscopic surgery

standard endoscopic surgery for recurrent nasopharyngeal carcinoma

Sponsors & Collaborators

  • Chinese Academy of Medical Sciences

    collaborator OTHER

  • Eye & ENT Hospital of Fudan University

    lead OTHER

Principal Investigators

  • Hongmeng Yu, MD,PHD · Eye&ENT Hospital,Fudan University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-10
Primary Completion
2025-08-10
Completion
2025-08-10

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05011227 on ClinicalTrials.gov